Arcturus Therapeutics Holdings Business Summary

Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage biotechnology firm specializing in the discovery and development of messenger RNA (mRNA) medicines, primarily generating revenue through high-value strategic collaborations, licensing agreements, and government grants. The company operates through a single business segment focused on its proprietary LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms, targeting infectious disease vaccines and rare respiratory and liver disorders. Its commercial-stage presence is anchored by the KOSTAIVE® COVID-19 vaccine in Japan, while its pipeline is led by ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency. Within the competitive landscape, Arcturus contends with industry giants such as Moderna and BioNTech, as well as specialized peers like Intellia Therapeutics and Sarepta Therapeutics, positioning itself as a differentiated leader in the niche of inhaled mRNA delivery and low-dose, long-lasting protein expression via sa-mRNA technology. Founded in 2013 by Joseph E. Payne and Dr. Padmanabh Chivukula, the leadership team possesses deep expertise in nucleic acid chemistry and nanoparticle delivery. Joseph E. Payne serves as President and CEO, bringing over two decades of drug discovery experience from Merck Research Labs and Bristol-Myers Squibb, while Dr. Chivukula, the Chief Scientific Officer and Chief Operating Officer, previously led RNAi research at Nitto Denko. The executive suite is further strengthened by CFO Andrew Sassine and Chief Development Officer Igor Smolenov. The company’s strategic direction is overseen by a notable Board of Directors chaired by Dr. Moncef Slaoui, former head of GSK’s vaccines department and leader of Operation Warp Speed. Arcturus maintains a robust institutional investor base, including significant positions held by Federated Hermes, BlackRock, ARK Investment Management, and the Vanguard Group.